Log In
Print this Print this

Lexgenleucel-T (VRX496)

  Manage Alerts
Collapse Summary General Information
Company Virxsys Corp.
DescriptionAutologous CD4+ T cells treated ex vivo with an HIV vector engineered to inhibit HIV replication and spread
Molecular Target Not applicable
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector
Latest Stage of DevelopmentPhase II
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today